Send comments and news tips to [email protected]. Cite this: Edited by Shrabasti Bhattacharya. Intensive Bevacizumab Boosts Vision in Macular Degeneration - Medscape - June 19, 2025.

The data set consisted of 3,106 glioblastoma tumor samples, of which 571 were from patients treated with bevacizumab. The majority were males (65%) and older than 60 years. Median survival was 17.5 ...

By the end of follow-up, we expected that osimertinib plus bevacizumab could better reduce the risk of intracranial progression and prolong the progression-free survival compared with osimertinib ...

BioDlink's Bevacizumab Injection has been granted marketing authorization by Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC), following GMP certifications in Brazil (a ...

ISELIN, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment ...

BioDlink's Bevacizumab Injection has been granted marketing authorization by Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC), following GMP certifications in Brazil ...

Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for use by the NHS in England and Wales for treating wet age-related macular ...

Bevacizumab combined with fluorouracil-based chemotherapy has become the standard for first-line treatment of metastatic colorectal cancer. It may prove useful for other tumors as well.

MHRA says it is okay for the NHS to prescribe Roche’s Avastin off-label for wet AMD amid a legal challenge from Bayer and Novartis ...

The researchers evaluated alectinib and bevacizumab in the phase 2 ALEK-B trial (NCT03779191), which included 41 patients with treatment-naïve, metastatic, ALK-rearranged NSCLC. The patients’ median ...